

ASX RELEASE

Volpara confirms Board changes to drive US growth

- **Volpara appoints highly experienced, US-based company director and healthcare senior executive Ann Custin as Non-Executive Director**
- **Ann brings 15+ years' executive leadership experience from leading European and American healthcare companies, including Siemens Medical Solutions and Draeger Medical Systems**
- **Ann is also Non-Executive Director of NASDAQ-listed women's health company Establishment Labs Holdings Inc. with a market capitalisation of ~US\$1.7 billion**
- **Non-Executive Director Dr Monica Saini retires from the Board to further her breast cancer screening practice**
- **Board changes executed to strengthen its US presence and drive the Company's growth as it continues to further commercialise its AI-powered software for personalised screening and early detection of breast cancer in the USA**

Wellington, NZ, 19 August 2021: Volpara Health Technologies ("Volpara," "the Group," or "the Company"; ASX:VHT), a global health technology software leader providing an integrated breast care platform for the delivery of personalised breast care, announces the following changes to its Board of Directors ("Board") to further enhance the Board's expertise around patient data and US healthcare networks and drive the Company's best-practice governance standards.

Highly experienced senior healthcare general manager and finance executive Ann Custin joins the Board as an independent, Non-Executive Director, effective 1 September 2021.

Ann brings a deep network of industry contacts from an extensive career in healthcare across Europe, the Americas, and Asia. Her most recent executive role was with Siemens Healthineers, where she served as both CFO and board director of Siemens Medical Solutions. Prior to this Ann served as chief operating and financial officer of Scient'x and President & CEO of USA Draeger Medical Systems, Inc.

Ann is also a Non-Executive Director of NASDAQ-listed Establishment Labs Holdings Inc., a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, that has a market capitalisation of approximately US\$1.7 billion.

Ann's remuneration will be in line with that of other Non-Executive Directors, including an equity component involving the grant of 450,000 options, which will be subject to shareholder approval at the AGM in August 2022.

The Company also announces that Non-Executive Director Dr Monica Saini has retired from the Volpara Board of Directors, effective 18 August 2021, as she focuses her efforts on direct patient care and health advocacy through her private breast cancer screening practice. Monica will remain closely linked to Volpara, using its products and providing input into future product development.

Paul Reid, Chair of Volpara, said: "We welcome Ann Custin, an experienced healthcare executive and board director in the United States, to the Board of Volpara. We are also sad to see Monica leave the Board, to pursue her own direct agenda to help save women's lives, but we thank her for her valuable contribution to the Board and the Company over the past three years. We wish her all the best with her new clinic in Wellington."

Authorisation & Additional Information

This announcement was authorised by the Board of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Corporate Enquiries

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparahealth.com
t: +64 21 149 0541

Media Enquiries

Trevor Chappell
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com